版本:
中国

BRIEF-TG Therapeutics says successful outcome from analysis in UNITY-CLL trial

May 23 TG Therapeutics Inc

* TG Therapeutics Inc. announces successful outcome from pre-planned interim analysis by independent DSMB in the UNITY-CLL Phase 3 trial

* TG Therapeutics Inc - found no safety concerns and recommended continuation of enrollment without modification in trial

* Says study will now continue enrollment in a 1:1 ratio to only two combination arms

* Says given current rate of enrollment, we are now targeting complete enrollment by year end

* Says expect to report pivotal overall response rate (orr) data in Q3 of 2018

* Says DSMB recommended company cease enrollment into single agent arms Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐